This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Non-Small Cell Lung Cancer Immunotherapy: Clinical Management

Non-Small Cell Lung Cancer Immunotherapy: Clinical Management

Format

Monograph

Time to Complete

30 minutes

Released

February 6, 2017

Expires

July 31, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Jointly provided by Postgraduate Institute for Medicine and The Society for Immunotherapy of Cancer

Commercial Supporter

Supported by an independent educational grant from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, and Merck & Co., Inc

Program Description

Presented through detailed written case studies, this activity is designed to provide physicians and registered nurses with a more in-depth overview of what they will need to know when considering and utilizing immunotherapy with non-small cell lung cancer (NSCLC) patients in the clinical setting.

Intended Audience

Physicians, oncologists, and other clinicians who treat patients with NSCLC

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Describe the key mechanisms and terminology of tumor immunology and cancer immunotherapy
  • Identify the current immunotherapy treatments for non-small cell lung cancer; including their mechanism of action, adverse events, clinical management, and efficacy
  • Incorporate immunotherapy in treatment regimens
  • Differentiate the side effects between immunotherapy treatments and traditional treatments for NSCLC in monitoring and educating

Conflicts of Interest Disclosure Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported any financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity under the Faculty section below.

Faculty

Maura Abbott, PhD, AOCNP, CPNP
Assistant Professor of Nursing
Oncology Program Director
Columbia University Medical Center

Dr. Abbott has no relevant financial relationships to disclose.

Jarushka Naidoo, MD
Assistant Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Dr. Naidoo has no relevant financial relationships to disclose.

The steering committee reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Julie Brahmer, MD, discloses the following:
Consulting Fees: Merck; BMS (non-compensated); Eli Lilly; Celgene
Contracted Research: BMS; MedImmune/AstraZeneca; Merck

Ann Lau Clark, RN, MSN, CCRP, CCRC
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (ie: Speakers' Bureau): BMS; Merck

Roy Herbst, MD, PhD, discloses the following:
Consulting Fees: Biothera; Diatech; Kolltan
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent (ie: Speakers' Bureau): AstraZeneca; Boehringer Ingelheim; Eli Lilly; Genentech/Roche; Merck; Pfizer
Contracted Research: Genentech; Merck

Naiyer Rizvi, MD, discloses the following:
Consulting Fees: AstraZeneca; Roche; Novartis; Merck
Ownership Interest: Gristone Oncology

Tanguy Seiwert, MD, discloses the following:
Consulting Fees: Amgen; AstraZeneca; BMS; Celgene; Merck/MSD; Merck Serono; Jounce

David Spigel, MD, discloses the following:
No relevant financial relationships to disclose.

Accredited Provider Disclosure

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Publishing Staff Disclosure

The following SITC planners and managers, Tara Withington, CAE, Mike Scorzo, Ed.D., and Lianne Wiggins hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions

In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 75% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine at information@pimed.com or (303) 799-1930.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue